Abstract-Hyperaldosteronism is associated with hypertension, cardiovascular fibrosis, and electrolyte disturbances, including hypomagnesemia. Mechanisms underlying aldosterone-mediated Mg 2ϩ changes are unclear, but the novel Mg 2ϩ transporters TRPM6 and TRPM7 may be important. We examined whether aldosterone influences renal TRPM6/7 and the TRPM7 downstream target annexin-1 and tested the hypothesis that Mg 2ϩ administration ameliorates aldosterone-induced cardiovascular and renal injury and prevents aldosterone-associated hypertension. C57B6 mice were studied (12 weeks, nϭ8 to 9/group); (1) control group (0.2% dietary Mg 2ϩ ), (2) Mg 2ϩ group (0.75% dietary Mg 2ϩ ), (3) aldosterone group (Aldo, 400 g/kg/min and 0.9% NaCl drinking water), and (4) AldoϩMg 2ϩ group. Blood pressure was unaltered by aldosterone and was similar in all groups throughout the experiment. Serum Na ϩ was increased and serum K ϩ and Mg 2ϩ decreased in the Aldo group. Aldo mice had hypomagnesuria and proteinuria, and renal, cardiac, and aortic fibrosis, which were normalized by Mg 2ϩ supplementation. Renal and cardiovascular expression of interleukin-6, VCAM1 and COX2 was increased in the Aldo group. Magnesium attenuated renal and cardiac interleukin-6 content and decreased renal VCAM1 and cardiac COX2 expression (PϽ0.05). Aldosterone decreased expression of renal TRPM7 and the downstream target annexin-1 (PϽ0.05) without effect on TRPM6. Whereas Mg 2ϩ increased mRNA expression of TRPM6 and TRPM7, it had no effect on TRPM7 and annexin-1 protein content. Our data demonstrate that aldosterone mediates blood pressure-independent renal and cardiovascular fibrosis and inflammation through Mg 2ϩ -sensitive pathways. We suggest that altered Mg 2ϩ metabolism in hyperaldosteronism may relate to TRPM7 downregulation and that Mg 2ϩ protects against cardiovascular and renal damaging actions of aldosterone. A ldosterone, classically thought to be produced by the zona glomerulosa of the adrenal cortex and implicated in the maintenance of sodium, potassium, and acid-base balance and blood pressure regulation, is now considered a hormone with pleiotropic actions, produced by multiple tissues, including the heart, vessels, kidney, and brain. 1,2 In addition to regulating renal electrolyte excretion, aldosterone contributes to vascular inflammation, oxidative stress, collagen deposition, and endothelial dysfunction. [3][4] [5] As such, aldosterone has been implicated in the development of cardiovascular and renal remodeling, fibrosis, and injury. The importance of these processes in clinical medicine is being increasingly recognized by the cardiovascular and renal protective effects of the aldosterone antagonists, spironolactone and eplerenone. 6, 7 The profibrotic and proinflammatory actions of aldosteronism are accompanied by disturbances in cation homeostasis including hypomagnesemia and decreased intracellular free magnesium concentration ([Mg 2ϩ ] i ). 8, 9 Recent evidence suggests that aldosterone-induced cardiovascular inflammation is induced, in part, by decreased [Mg 2ϩ ] i with Ca 2ϩ loading leading to increased H 2 O 2 formation and cellular oxidative stress. 8 -10 Hyperaldosteronism-associated renal magnesium wasting and cardiovascular injury and fibrosis are ameliorated by spironolactone and eplerenone and by Mg 2ϩ administration. 6, 7, 11 Mechanisms whereby aldosterone causes Mg 2ϩ depletion are unclear, but the recently identified novel magnesium transporters, transient receptor potential melastatin cation channels 6 and 7 (TRPM6 and TRPM7), may be important. 12,13 Both proteins share the unique feature of an atypical kinase domain at their C terminus and are negatively regulated by intracellular Mg 2ϩ levels. 14,15 TRPM6 and TRPM7 have been described as the "gatekeepers" of human Mg 2ϩ metabolism, but may also play a role in intracellular signaling events, because TRPM7 kinase activates downstream targets annexin-1, calpain, and myosin IIA heavy
A ldosterone, classically thought to be produced by the zona glomerulosa of the adrenal cortex and implicated in the maintenance of sodium, potassium, and acid-base balance and blood pressure regulation, is now considered a hormone with pleiotropic actions, produced by multiple tissues, including the heart, vessels, kidney, and brain. 1, 2 In addition to regulating renal electrolyte excretion, aldosterone contributes to vascular inflammation, oxidative stress, collagen deposition, and endothelial dysfunction. [3] [4] [5] As such, aldosterone has been implicated in the development of cardiovascular and renal remodeling, fibrosis, and injury. The importance of these processes in clinical medicine is being increasingly recognized by the cardiovascular and renal protective effects of the aldosterone antagonists, spironolactone and eplerenone. 6, 7 The profibrotic and proinflammatory actions of aldosteronism are accompanied by disturbances in cation homeostasis including hypomagnesemia and decreased intracellular free magnesium concentration ([Mg 2ϩ ] i ). 8, 9 Recent evidence suggests that aldosterone-induced cardiovascular inflammation is induced, in part, by decreased [Mg 2ϩ ] i with Ca 2ϩ loading leading to increased H 2 O 2 formation and cellular oxidative stress. 8 -10 Hyperaldosteronism-associated renal magnesium wasting and cardiovascular injury and fibrosis are ameliorated by spironolactone and eplerenone and by Mg 2ϩ administration. 6, 7, 11 Mechanisms whereby aldosterone causes Mg 2ϩ depletion are unclear, but the recently identified novel magnesium transporters, transient receptor potential melastatin cation channels 6 and 7 (TRPM6 and TRPM7), may be important. 12, 13 Both proteins share the unique feature of an atypical kinase domain at their C terminus and are negatively regulated by intracellular Mg 2ϩ levels. 14, 15 TRPM6 and TRPM7 have been described as the "gatekeepers" of human Mg 2ϩ metabolism, but may also play a role in intracellular signaling events, because TRPM7 kinase activates downstream targets annexin-1, calpain, and myosin IIA heavy chain. 12,13,16 -19 TRPM7 is an important player in cellular Mg 2ϩ homeostasis whereas TRPM6 appears to be more important in epithelial Mg 2ϩ transport. 13, 16 Patients with loss-of-function mutations in TRPM6 exhibit a severe form of hereditary hypomagnesaemia (primary hypomagnesaemia with secondary hypocalcaemia [HSH] ). 20 We demonstrated that vasoactive agents, including angiotensin II and aldosterone, regulate vascular TRPM7 expression and activity and that TRPM7 plays a critical role in vascular smooth muscle cell (VSMC) transcellular Mg 2ϩ transport and [Mg 2ϩ ] i homeostasis. 21, 22 The effect of aldosterone on renal TRPM6/7 status is unknown.
In the present in vivo study we sought to determine whether aldosterone influences renal TRPM6/7 expression and the TRPM7 downstream target annexin-1 and tested the hypothesis that Mg 2ϩ administration ameliorates aldosteronemediated cardiovascular and renal injury and prevents aldosterone-induced hypertension in mice.
Materials and Methods
An expanded Methods section is available in an online data supplement at http//hyper.ahajournals.org.
Animals
This study was approved by the Animal Ethics Committee of the University of Ottawa and performed according to the recommendations of the Canadian Council for Animal Care. Four groups of 12-week-old male C57B6 mice (Jackson Laboratory, Maine, Del) were studied: Control (normal mouse chow; Harlan Teklad Global Diet:2018; 0.2% dietary Mg 2ϩ , nϭ8), magnesium-supplemented group (Mg 2ϩ group; 0.75% dietary Mg 2ϩ , Harlan Teklad, nϭ9), aldosterone-infused group (Aldo group; 300 g/kg/d for 2 wk then 400 g/kg/d by Alzet osmotic mini-pumps and 0.9% NaCl drinking water, nϭ9) and AldoϩMg 2ϩ group (aldosterone infusion, 0.9% NaCl drinking water and 0.75% dietary Mg 2ϩ nϭ9).
Blood Pressure Measurements and Serum and Urine Analysis
The systolic blood pressure (SBP) was measured in conscious mice every 3 days using the Visitech tail cuff system (BP 2000 Blood Pressure Analysis System, Visitech). Blood and urine were collected at the beginning and end of the experiment. Levels of Mg 2ϩ , Ca 2ϩ , Na ϩ , and K ϩ and urine protein were measured by automated methods at the hospital laboratory.
Analysis of TRPM6 and TPRM7 mRNA Levels With Real-Time Polymerase Chain Reaction
Frozen kidney samples were homogenized and RNA extracted using Trizol reagent (Invitrogen). 200 ng of each RNA sample was reverse transcribed using random hexamers and TaqMan reverse transcription (RT) reagents (Applied Biosystems). Specific primers and FAM-labeled probes for mouse TRPM6 and TRPM7 were designed using Primer Express software (Applied Biosystems) and sequences from the NCBI database (Table S1 ). All reactions were performed in triplicate, and a standard curve constructed on each plate using an independent control sample of kidney cDNA. The PCR conditions were: 50°C for 2 minutes, 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute (Applied Biosystems 7300 Real-time PCR system). Relative expressions of TRPM6 and TRPM7 in the unknown samples were determined from a standard curve and expressed relative to 18S.
Western Blotting
Proteins from kidney (renal cortex), heart, and aorta were extracted from frozen tissue as previously described. 22 Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and incubated with specific antibodies to VCAM1 (Santa Cruz Biotechnology), COX2 (Cayman chemical), TRPM7 (Abcam), annexin-1 (Santa Cruz Biotechnology). Signals were revealed by chemiluminescence, visualized autoradiographically, and subsequently membranes were stripped (Pierce Biotechnology) and reprobed with GAPDH or ␣-actin antibodies (Chemicon International), which were used as internal controls. Optical density of bands was quantified densitometrically. 
Histopathologic Analysis
Tissues were fixed in 4% formaldehyde solution for 24 hours at 4°C, dehydrated, embedded in paraffin, and sectioned transversely (4 m). Sections were stained with hematoxylin and Sirius red and scored for vascular damage and collagen deposition.
Immunohistochemistry
Frozen tissue (kidney, heart apex, and aorta) were cryosectioned (7 m thickness) and fixed with cold acetone for 10 min. For direct immunohistochemistry, sections were incubated with 3% H 2 O 2 and a Pierce solution to block endogenous peroxidase and biotin, respectively, followed by overnight incubation (humidified box, 4°C) with a biotinated antigoat IL-6 monoclonal antibody (Santa Cruz). Sections were lightly stained in hematoxylin, dehydrated with alcohol and xylene, and scored by an independent observer unaware of the groups and treatments of the mice.
Data Analysis
Values are expressed as meansϮSEM, with n indicating the number of mice. Two-way ANOVA was used to evaluate differences between the groups followed by Tukey Kramer post hoc testing. Data are presented as the effects of Mg 2ϩ , Aldo, and AldoϩMg 2ϩ . PϽ0.05 was considered to be statistically significant. For evaluation of Western blot data, controls were normalized to 100% and experimental groups compared to controls (taken as 100%).
Results

Body Weight and Cardiac and Renal Size
Mice in all groups thrived with similar body weights at the end of the experimental period (Table 1) . Heart and kidney size, corrected for tibial length, were significantly greater in the aldosterone-treated groups compared with control counterparts (heart, 6.88Ϯ0.17 versus 8.38Ϯ0.46, PϽ0.05; kidney, 1.94Ϯ0.04 versus 2.63Ϯ0.12, PϽ0.001). In magnesium-supplemented aldosterone-treated mice, cardiac size was not different from the control group, but kidney size was significantly increased versus controls (PϽ0.01).
Blood Pressure
Mice were treated for 3 months with aldosterone. They also received 0.9% NaCl in the drinking water. Aldosterone was infused initially at a dose of 300 g/kg/min. Because blood pressure did not increase after 2 weeks infusion at this dose, we increased the aldosterone concentration to 400 g/kg/min until the end of the experiment. Aldosterone failed to increase SBP, even at the higher dose of infusion ( Figure S1 ). Magnesium supplementation did not influence blood pressure in control or aldosterone-treated mice.
Serum and Urine Biochemistry
Serum and urine biochemistry was similar in all groups at the beginning of the experiment. Table 1 demonstrates serum and urine cation and urine proteins levels in the different groups at the end of the experimental period. Serum Mg 2ϩ was significantly increased in the magnesium-supplemented groups versus other groups (PϽ0.01). Serum Na ϩ was increased and serum K ϩ was decreased in the aldosteroneinfused mice, without effect of magnesium supplementation. Serum Ca 2ϩ was similar in all groups. Serum Mg 2ϩ was reduced in the aldosterone group, but did not reach significance (PϽ0.06).
Urinary Mg 2ϩ levels were significantly increased in the Mg 2ϩ -supplemented groups (Table 1) . Aldosterone infusion was associated with significantly reduced Na ϩ and Mg 2ϩ levels, which were normalized by Mg 2ϩ supplementation. Aldosterone-infused mice exhibited significant proteinuria, which was ameliorated by Mg 2ϩ .
Renal Effects of Aldosterone and Magnesium Supplementation
Renal fibrillar collagen deposition was increased in aldosterone-treated animals ( Table 2 ). This was associated with an increased inflammatory response as evidenced by increased expression of IL-6, VCAM1, and COX2 (Figures 1 through  3 ). Magnesium supplementation did not influence renal fibrosis or inflammatory mediators in the control group, but significantly decreased effects in the aldosterone-treated group.
Effects of Aldosterone and Magnesium on Renal Expression of TRPM6 and TRPM7
As shown in (Figure 4 ), aldosterone had no effect on mRNA expression of TRPM6, but significantly reduced TRPM7 mRNA content (PϽ0.05). Magnesium supplementation in- Figure 1 . Renal collagen deposition in the 4 groups. Renal sections were stained with Sirius red, and collagen content was assessed using a standard grading scheme ( Collagen content was assessed qualitatively according to the intensity of staining with a scale of Ϫ (no staining) to ϩϩϩ (heavy staining).
Grading of staining: Ϫ no change, ϩ mild, ϩϩ moderate, ϩϩϩ severe.
creased expression of TRPM6 and TRPM7 in aldosteroneinfused mice (PϽ0.01). In control mice, TRPM7 mRNA expression was increased by Mg 2ϩ (PϽ0.05, t test). At the protein level, we evaluated expression of TRPM7, but not of TRPM6, because only TRPM7 gene seemed to be influenced by aldosterone, confirming our previous studies. 22 Moreover it is very difficult to accurately assess TRPM6 protein because of the unavailability of sensitive anti-TRPM6 antibodies. As demonstrated in (Figure 5 ), protein content of renal TRPM7 and its downstream substrate annexin-1 was significantly reduced in the aldosterone group. This was unaffected by Mg 2ϩ ( Figure 5 ).
Cardiovascular Effects of Aldosterone and Magnesium Supplementation
As observed in the kidney, collagen deposition was significantly increased in the heart in response to aldosterone ( Figure 6 ). This effect was attenuated in mice supplemented with Mg 2ϩ . Expression of cardiac IL-6, VCAM, and COX2 was significantly enhanced in the aldosterone group ( Figures  S2 and S3 ). Magnesium reduced IL-6 and COX2 expression, but did not influence cardiac VCAM1 expression.
Aortic collagen content and media thickness were significantly increased in the aldosterone-infused mice versus controls (53.91Ϯ1.8 versus 116Ϯ13.61, PϽ0.01) (Table 2, Figure 7 ). Magnesium significantly reduced the media thickness of the aorta (116Ϯ13.61 versus 68.04Ϯ2.09, Aldo versus AldoϩMg; PϽ0.05). Vascular expression of VCAM1 and COX2 was significantly increased in the aldosteronetreated mice (PϽ0.05) ( Figure S4 ). Magnesium supplementation did not influence expression of proinflammatory mediators in the aorta.
Discussion
Major findings from the present study demonstrate that in C57B6 mice (1) aldosterone induces significant renal and cardiovascular hypertrophy, fibrosis, and inflammation independently of blood pressure elevation, (2) Mg 2ϩ supplementation attenuates aldosterone-mediated cardiovascular and renal remodeling, (3) aldosterone decreases renal expression of the novel Mg 2ϩ transporter TRPM7, but not TRPM6, and the TRPM7 downstream target annexin-1, and (4) Mg 2ϩ administration prevents aldosterone-induced renal dysfunction (proteinuria) and electrolyte disturbances. Our findings highlight the potent profibrotic and proinflammatory actions of aldosterone in the heart, vasculature, and kidneys and suggest that Mg 2ϩ plays a role in these processes. We also provide the first evidence that aldosterone modulates renal TRPM7 expression, which could be important in altered Mg 2ϩ homeostasis associated with hyperaldosteronism. 8, 9, 23 An unexpected finding in our study was the failure of aldosterone to induce hypertension. This may relate to the fact that the mice investigated here were not uninephrectomized as in many other studies. Moreover, we studied C57B6 mice, which seem to be resistant to hypertensive-inducing stimuli. 24 -26 Other studies have also reported variable blood pressure actions of aldosterone, with some studies reporting a significant hypertensive effect and others showing no change in blood pressure. 24 -26 To ensure that the methodology used to measure blood pressure in our study was reliable, we performed a second set of experiments where mice were infused with Ang II (400 ng/mg/min). These mice developed hypertension within 3 days (SBPϷ160 mm Hg), similar to our previous studies indicating that the tail cuff technique used was functional. The fact that aldosterone did not cause hypertension yet induced marked cardiac, vascular, and renal remodeling as well as renal dysfunction (proteinuria) suggests that it has direct cardiovascular/renal effects independently of changes in blood pressure. This is supported by extensive experimental data indicating that aldosterone directly stimulates cell proliferation, hypertrophy, collagen deposition, and inflammation. [27] [28] [29] Molecular mechanisms underlying these processes involve activation of MAP kinases, tyrosine kinases, NADPH oxidase-derived reactive oxygen species, and proinflammatory transcription factors, mediated through genomic and nongenomic pathways. 1 observed in the magnesium-supplemented group. Considering that our experiment was a long-term study, we cannot exclude the possibility that some of the observed cardiovascular and renal changes may be secondary to aldosterone-induced electrolyte alterations. Nevertheless, the initiating stimulus was aldosterone, indicating that this hormone does play a role in the process. Hence, in chronic in vivo studies, aldosterone effects may be both direct and indirect.
Magnesium has important antiinflammatory and antioxidant properties. Mg 2ϩ -deficient mice exhibit severe cardiovascular inflammation and oxidative injury, which are normalized by Mg 2ϩ supplementation. 34, 35 In our study, dietary Mg 2ϩ ameliorated aldosterone-induced damaging actions and reduced fibrosis in the kidney, heart, and aorta, similar to effects previously reported. 10 We examined expression of IL-6, a secondary cytokine, VCAM1, a proinflammatory adhesion molecule and COX2, a key enzyme involved in the inflammatory response. Although aldosterone significantly increased expression of all of these mediators, the antiinflammatory response of Mg 2ϩ was variable, with major effects in kidney and heart and little effect in the aorta. Reasons for this regional heterogeneity are unclear but may relate to differences in [Mg 2ϩ ] i in the different tissues. In support of our findings, Kramer et al also reported variable effects of dietary Mg 2ϩ on circulating proinflammatory mediators in cardiac disease. 36 It is also possible that Mg 2ϩ actions are tissuespecific. For example in the aorta of Mg 2ϩ supplemented mice, remodeling was markedly improved, whereas inflammatory responses were not, suggesting that in the vasculature effects on fibrosis and growth by Mg 2ϩ may be more important than effects on inflammation.
Extensive clinical and experimental evidence indicates that hyperaldosteronism causes electrolyte changes, specifically hypokalemia, hypernatremia, and hypomagnesemia. 8, 9 In the aldosterone-infused mice, serum Na ϩ was increased and serum K ϩ was decreased confirming efficient absorption of the administered aldosterone. Reasons for these electrolytes changes are attributable to renal actions of aldosterone, which promote K ϩ excretion and Na ϩ reabsorption through activation of the Na ϩ /H ϩ exchanger, ENaC, and Na ϩ /K ϩ ATPase transporters. 1 In our study, serum Mg 2ϩ tended to be lower in the aldosterone group. Urine Mg 2ϩ was significantly reduced. These findings are in contrast to those reported by Runyan et al 8 and Chhokar et al, 37 where aldosterone infusion induced hypermagnesuria. However, in those studies, 8, 37 rats, not mice, were investigated, uninephrectomy was performed, and animals were infused for 4 to 6 wk. Hence the experimental protocol was different from our study. Reasons for hypomagnesuria and relative hypomagnesemia in our aldosteroneinfused mice may relate to downregulation of renal TRPM7 and to redistributon of Mg 2ϩ in muscle, bone, and the gastrointestinal tract. Although we did not measure activity of TRPM7 directly, we assessed annexin-1 status, which paralleled TRPM7 changes. Annexin-1 is a TRPM7 kinasesensitive substrate 12 that has been implicated in inflammation, cell proliferation, and apoptosis. 38 Another mechanism whereby aldosterone may influence urinary Mg 2ϩ excretion is through the Na ϩ /Mg 2ϩ exchanger, which we demonstrated to be upregulated in hypertension. 39 Hence altered Mg 2ϩ metabolism in hyperaldosteronism may be related to direct stimulation of the Na ϩ /Mg 2ϩ exchanger on the one hand and to downregulation of TRPM7 on the other.
Cellular models demonstrate that TRPM6 and TRPM7 are regulated by Mg 2ϩ . 14, 15 We speculated that Mg 2ϩ supplementation would normalize TRPM7 in aldosterone-treated mice. This was confirmed at the gene level, where mRNA expression of TRPM6 and TRPM7 was significantly increased in aldosterone-infused mice receiving Mg 2ϩ . However, this was not evident at the protein level, because TRPM7 and annexin-1 content were not normalized in Mg 2ϩ supplemented mice. Reasons for these differences between gene and protein status might relate to mRNA instability, transcriptional changes, or to changes at the posttranslational levels. It may also be possible that tissue [Mg 2ϩ ] i was not high enough to influence TRPM7 protein expression.
In conclusion, data from the present study demonstrate that aldosterone mediates blood pressure-independent renal and cardiovascular fibrosis and inflammation and electrolyte disturbances through Mg 2ϩ -sensitive pathways. We also report the novel findings that aldosterone induces downregulation of renal TRPM7 and annexin-1. These findings suggest that altered Mg 2ϩ metabolism in hyperaldosteronism may relate to TRPM7 dysregulation and that Mg 2ϩ protects against cardiovascular and renal damaging actions of aldosterone.
Perspectives
Hyperaldosteronism, the incidence of which is increasing in clinical medicine, is associated with hypomagnesemia, hypertension, and cardiovascular remodeling. Mechanisms contributing to these processes, and particularly to aldosteroneassociated Mg 2ϩ changes, are unclear. Experimental evidence suggests that impaired transmembrane Mg 2ϩ transport through TRPM6/7 channels may be important. Our data demonstrate that aldosterone mediates blood pressureindependent renal and cardiovascular fibrosis and inflammation and renal dysfunction, which are ameliorated by dietary Mg 2ϩ -supplementation. We also show that aldosterone induces downregulation of renal TRPM7 and its target annexin-1. Hence altered Mg 2ϩ metabolism in aldosteronism may relate to TRPM7 dysregulation. Magnesium has cardiovascular protective effects and prevents renal damage and 
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Materials and methods
Animals
Blood pressure measurements
The systolic blood pressure (SBP) was measure in conscious mice every 3 days using the Visitech tail cuff system (BP 2000 Blood Pressure Analysis System, Visitech, Apex, NC). The mice were immobilized on a warmed platform at 37 • C. One week before commencing the experiment, mice were trained daily using the Visitech system. For blood pressure measurements, the first 5 recordings were disregarded and the average of the 10 successive measurements taken as the final blood pressure reading.
Serum and urine analysis
Blood and urine were collected at the beginning and end of the experiment. Blood was collected by venesection from the saphenous vein (300-500 µL). Mice were placed in metabolic cages for 24 hours for urine collection. Serum and urine levels of Mg Real-time PCR protocol. Specific primers and FAM-labeled probes for mouse TRPM6 and TRPM7 were designed using Primer Express software (Applied Biosystems) and sequences from the NCBI database (table S1 ). Primer and probe sets for both genes were designed to span an exon-exon junction to avoid amplification of genomic DNA. Primers Relative expressions of TRPM6 and TRPM7 in the unknown samples were determined from the standard curve, and expressed relative to 18S.
Western blotting
Proteins from kidney (renal cortex), heart and aorta were extracted from frozen tissue as previously described (1- 
Histopathological analysis
Tissues were fixed in 4% formaldehyde solution for 24h at 4°C, dehydrated, embedded in paraffin and sectioned transversely (4 µm). Sections were stained with hematoxylin and Sirius red and scored for vascular damage and collagen deposition as we previously described (4). Samples were examined with a Nikon Eclipse E600 microscope (Nikon Corporation, Kanagawa, Japan). Images were captured using the image Pro Plus software computer program (Ipwin 32, Media Cybernetics, L.P., Maryland, USA).
Immunohistochemistry
Frozen tissue (kidney, heart apex and aorta) were cryosectioned (7 µm thickness) and fixed with cold acetone for 10 minutes. For direct immunohistochemistry, sections were incubated with 3 % H 2 O 2 and a Pierce solution to block endogenous peroxidase and biotin, respectively, followed by overnight incubation (humidified box, 4°C) with a biotinated anti-goat interleukin-6 (IL-6) monoclonal antibody (Santa Cruz). Sections were incubated for 60 minutes with a secondary biotin-conjugated anti-rabbit antibody
(1:1500 in 2 % horse serum: Rockland) and with streptavidin conjugated to horseradish peroxidases (Vector Labs). Color was developed by the addition of DAB (Sigma Chemicals). Sections were lightly stained in hematoxylin, dehydrated with alcohol and xylene, and scored by an independent observer unaware of the groups and treatments of the mice. To normalize for background staining, procedures were also performed in sections incubated only with the secondary antibody.
Results
Blood pressure
Mice were treated for 3 months with aldosterone. They also received 0.9% NaCl in the drinking water. Aldosterone was infused initially at a dose of 300 µg/kg/min. Since blood pressure did not increase after 2 weeks infusion at this dose, we increased the aldosterone concentration to 400µg/kg/min until the end of the experiment. Aldosterone failed to increase SBP, even at the higher dose of infusion ( Figure S1 ). Magnesium supplementation did not influence blood pressure in control or aldosterone-treated mice.
Cardiovascular effects of aldosterone and magnesium supplementation
As observed in the kidney, collagen deposition was significantly increased in the heart in response to aldosterone. This effect was attenuated in mice supplemented with Mg
2+
.
Expression of cardiac IL-6, VCAM and COX2 was significantly enhanced in the aldosterone group (figures S2, S3). Magnesium reduced IL-6 and COX2 expression, but did not influence cardiac VCAM1 expression.
Vascular expression of VCAM1 and COX2
Vascular expression of VCAM1 and COX2 was significantly increased in the aldosterone-treated mice (p<0.05) ( figure S4 ). Magnesium supplementation did not influence expression of pro-inflammatory mediators in the aorta. 
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